Go Pro
NASDAQ:SANA

Sana Biotechnology Q3 2025 Earnings Report

Sana Biotechnology logo
$2.94 -0.02 (-0.68%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$2.96 +0.02 (+0.51%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sana Biotechnology EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Sana Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sana Biotechnology Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Sana Biotechnology's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sana Biotechnology Earnings Headlines

Sana Biotechnology (SANA)
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Sana Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email.

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biotechnology company focused on developing engineered cells and gene therapies for the treatment of serious diseases. The company’s approach is designed to create therapeutic cells that can be delivered to patients without requiring individualized manufacturing, potentially broadening access to cell-based medicines.

Sana is developing technologies intended to address key challenges in cell and gene therapy, including immune rejection, targeted delivery of genetic material and the production of engineered cells at scale. Its research programs have included cell therapies for oncology and autoimmune diseases, as well as approaches involving induced pluripotent stem cells and allogeneic, or donor-derived, therapeutic cells.

Founded in 2018 and headquartered in Seattle, Washington, Sana became a publicly traded company on the Nasdaq under the symbol SANA in 2021. The company’s operations are primarily focused on research and clinical development, with programs being advanced through clinical studies and other development activities. Sana has been led by Chief Executive Officer Steve Harr, who has experience in the biotechnology and pharmaceutical industries.

View Sana Biotechnology Profile